BioAge Labs (NASDAQ:BIOA) Given New $52.00 Price Target at Citigroup

BioAge Labs (NASDAQ:BIOA) had its target price hoisted by investment analysts at Citigroup from $15.00 to $52.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s target price would indicate a potential upside of 148.71% from the company’s current price.

Other research analysts also recently issued reports about the company. Oppenheimer began coverage on BioAge Labs in a report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, January 27th. Morgan Stanley set a $23.00 price objective on BioAge Labs in a report on Wednesday, February 4th. Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a research report on Tuesday, February 3rd. Finally, Piper Sandler began coverage on BioAge Labs in a report on Tuesday, January 27th. They issued an “overweight” rating for the company. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, BioAge Labs has an average rating of “Moderate Buy” and an average price target of $45.00.

BioAge Labs Stock Up 6.0%

Shares of BIOA traded up $1.18 on Tuesday, hitting $20.91. The company’s stock had a trading volume of 430,238 shares, compared to its average volume of 756,808. The firm has a market capitalization of $749.55 million, a price-to-earnings ratio of -13.75 and a beta of 1.21. The firm’s fifty day moving average price is $19.11 and its 200-day moving average price is $11.68. BioAge Labs has a fifty-two week low of $2.88 and a fifty-two week high of $24.00.

Insider Transactions at BioAge Labs

In related news, CFO Dov A. Md Goldstein sold 27,000 shares of BioAge Labs stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the sale, the chief financial officer owned 22,408 shares of the company’s stock, valued at approximately $441,437.60. The trade was a 54.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Kristen Fortney sold 233,107 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the completion of the transaction, the chief executive officer directly owned 976,949 shares in the company, valued at approximately $17,702,315.88. This represents a 19.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 267,540 shares of company stock worth $4,895,168. 20.82% of the stock is owned by insiders.

Hedge Funds Weigh In On BioAge Labs

Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. bought a new stake in BioAge Labs in the 4th quarter valued at about $3,025,000. XTX Topco Ltd acquired a new stake in shares of BioAge Labs in the fourth quarter valued at approximately $486,000. Sphera Funds Management LTD. acquired a new stake in BioAge Labs during the fourth quarter worth approximately $3,215,000. Quadrature Capital Ltd increased its stake in BioAge Labs by 56.2% during the 4th quarter. Quadrature Capital Ltd now owns 16,769 shares of the company’s stock worth $222,000 after acquiring an additional 6,035 shares during the period. Finally, Janus Henderson Group PLC acquired a new position in BioAge Labs in the 4th quarter valued at $5,406,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.